AbbVie releases new GARNET trial data

AbbVie recently released new data from its Phase 3 GARNET study involving the combination of VIEKIRAX and EXVIERA that shows significant response rates after only eight weeks of the medication.

The data shows that the response rate of 98 percent of patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) who were previously untreated were consistent at the 12-week mark of the study.

"VIEKIRAX + EXVIERA has already achieved high cure rates with 12 weeks of treatment," Chief of the Department of Medicine at J.W. Goethe University Hospital, Frankfurt, Germany, and author of the study Dr. Stefan Zeuzem said. "These results now show the potential for cure in just eight weeks with VIEKIRAX + EXVIERA in HCV genotype 1b infected patients without liver cirrhosis. The efficacy in this population is particularly important as GT1b is the most common subtype of hepatitis C virus globally."

There are more than 160 million people globally who have HCV.

"AbbVie remains focused on continuing to explore and understand the expectations of HCV care, including a shorter treatment duration with VIEKIRAX + EXVIERA in GT1b patients," AbbVie VP of Development and CMO Dr. Rob Scott said.